Study identifier:D3560L00089
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Audit and screening study to determine the prevalence of peripheral arterial disease. A cross-sectional multi-centre clinical study in subjects with cardiovascular disease risk factors.
Peripheral Arterial Disease
N/A
No
-
All
1000
Interventional
45 Years +
Allocation: N/A
Endpoint Classification: N/A
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
Pretium Pty Ltd
The primary objective of the study is to establish the prevalence of lower extremity peripheral arterial disease (PAD), defined as an ankle-brachial index of less than or equal to 0.9, in subjects with at least two of the specified cardiovascular disease (CVD) risk factors, with no overt cardiovascular disease.
Location
Location
Aspley, QLD, Australia
Location
Beulah Park, SA, Australia
Location
Booragoon, WA, Australia
Location
Bridgewater, TAS, Australia
Location
Brighton, VIC, Australia
Location
East Victoria Park, WA, Australia
Location
Edgecliff, NSW, Australia
Location
Glenelg East, SA, Australia
Arms | Assigned Interventions |
---|---|
Other: All Subjects ABI Screening Test Population: Subjects of either sex, any race, with at least two of the specified CVD risk factors, with no overt cardiovascular disease. | Procedure/Surgery: Ankle-brachial index (ABI) Screening Test Patients will undergo an ABI measurement |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.